NB1011 induces Ser15 phosphorylation of p53 and activates the G2/M checkpoint

Anti-Cancer Drugs

Volumn 14, Issue 6, 2003, Pages 449-455

  Dellinger, Ryan W ^a   Karjian, Patricia L ^a   Neuteboom, Saskia T C ^a  

^a NewBiotics Inc   (United States)

Author keywords

Cancer; G2 M checkpoint; NB1011; p53; Thymidylate synthase

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; CELL CYCLE PROTEIN; CYCLIN B1; MESSENGER RNA; NB 1011; PHOSPHORAMIDIC ACID DERIVATIVE; PROTEIN 14 3 3; PROTEIN KINASE; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; THYMIDYLATE SYNTHASE;

ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE PHASE; CELL STRAIN MCF 7; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; RNA ANALYSIS;

ADENOCARCINOMA; BREAST NEOPLASMS; BROMODEOXYURIDINE; COLONIC NEOPLASMS; HUMANS; PHOSPHORYLATION; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0043128608     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200307000-00011     Document Type: Article

References (33)

1. Van Triest B, Peters GJ. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 1999; 57:179-194.
2. Gorlick R, Bertino JR. Drug resistance in colon cancer. Semin Oncol 1999; 26:606-611.
3. Banerjee D, Gorlick R, Liefshitz A, Danenberg K, Danenberg PC, Danenberg PV, et al. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with Levels of thymidylate synthase. Cancer Res 2000; 60:2365-2367.
4. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995; 49:1419-1426.
5. Lonn U, Lonn S, Nilsson B, Stenkvist B. Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy. Cancer 1996; 77:107-112.
6. Rooney PH, Stevenson DA, Marsh S, Johnston PG, Haites NE, Cassidy J, et al. Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. Cancer Res 1998; 58:5042-5045.
7. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55:1407-1412.
8. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion to 5-fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15:3223-3229.
9. Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E, Ardalan B. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am 1999; 5:34-40.
10. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, et al. Thymidyiate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 1999; 5:1996-1999.
11. Li Q, Boyer C, Lee JY, Shepard HM. A novel approach to thymidylate synthase as a target for cancer chemotherapy. Mol Pharmacol 2001; 59:446-452.
12. Neuteboom STC, Karjian PL, Boyer C, Beryt M, Pegram M, Wahl GM, Shepard NM. Inhibition of cell growth by NB1011 requires high thymidyiate synthase levels and correlates with p53, p21, Bax and GADD45 induction. Mol Cancer Ther 2002; 1:377-384.
13. Vousden KH. Activation of the p53 tumor suppressor protein. Biochem Biophys Acta 2002; 1602:47-59.
14. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 21:587-597.
15. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1 a potential mediator of p53 tumor suppression. Cell 1993; 75:817-825.
16. 2/M progression. Mol Cell 1997; 1:3-11.
17. 2/M transition by p53. Oncogene 2001; 20:1803-1815.
18. 2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 1999; 96;2147-2152.
19. Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH, Shin DY. p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 1999; 274:29677-29682.
20. Drake JC, Allegra CJ, Moran RG, Johnston PG. Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines. Biochem Pharmacol 1996; 51:1349-1355.
21. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998; 281:1674-1677.
22. Canman CE, Lira DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998; 281:1677-1679.
23. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998; 20:398-400.
24. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999; 13:152-157.
25. Krause K, Haugwitz U, Wasner M, Wiedmann M, Mossner J, Engeland K. Expression of the cell cycle phosphatase cdc25C is down-regulated by the tumor suppressor protein p53 but not by p73. Biochem Biophys Res Commun 2001; 284:743-750.
26. Ohi R, Gould KL. Regulating the onset of mitosis. Curr Opin Cell Biol 1999; 11:267-273.
27. Yang J, Kornbluth S. All aboard the cyclin train: subcellular trafficking of cyclins and their CDK partners. Trends Cell Biol 1999; 9:207-210.
28. Takizawa CG, Morgan DO. Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol 2000; 12:658-665.
29. Pines J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem J 1995; 308:697-711.
30. Strausfeld U, Labbe JC, Fesquet D, Cavadore JC, Picard A, Sadhu K, et al. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 1991; 351:242-245.
31. 2 checkpoint control: regulation of 14-3-3 protein bindin9 by phosphorylation of Cdc25C on serine-216. Science 1997; 277:1501-1505.
32. Graves PR, Lovly CM, Uy GL, Piwnica-Worms H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene 2001; 20:1839-1851.
33. Sergeeva M, Cathers B. Cellular transformation of the investigational new anticancer drug NB1011, a phosphoramidate of 5-(2-bromovinyl)-2′/deoxyuridine, results in the modification of cellular proteins not DNA. Biochem Pharmacol 2003; 65:823-831.